Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials-Reference-Cited by-同舟云学术

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

Published:2022-06-08 Issue:1 Volume:10 Page:
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Fan Lin¹,Zhang Yuanyuan²,Maguire Peter²,Muston Dominic¹,Monberg Matthew³,Earla Jagadeswara Rao³,Mihai Adela⁴,Gulati Poonam⁵

Affiliation:

1. Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USA

2. Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UK

3. Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USA

4. Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UK

5. Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UK

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/20016689.2022.2078474

Reference41 articles.

1. SEER. Cancer stat facts. 2021; https://seer.cancer.gov/statfacts/more.html

2. USCS. U.S. cancer statistics data visualizations tool, based on 2020 submission data (1999-2018). 2021; https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/

3. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies

4. An Overview of PARP Inhibitors for the Treatment of Breast Cancer

5. Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis;Gynecologic Oncology;2023-01